Antibody-drug conjugates (ADCs) consist of linkers, payloads, and monoclonal antibodies (mAbs). They combine the advantages of high specificity targeting and potent cytotoxic effects, achieving precise and efficient elimination of cancer cells, making them a hot topic in cancer drug development. Since the first ADC drug Mylotarg® was approved by the FDA in 2000, as of … Read more
Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin, trade name: Mylotarg) was approved for the treatment of CD33-positive acute myeloid … Read more
Introduction Antibody-drug conjugates(ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. ADC consists of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the drug … Read more
What Is ADC? Antibody-drug conjugates (ADC) are a new type of targeted therapeutic drug, composed of monoclonal antibodies that specifically target antigens linked to small molecule cytotoxic drugs via linkers. They combine the powerful killing effect of traditional small molecule chemotherapy with the tumor-targeting capability of antibody drugs. This structure allowsADC to deliver drugs directly … Read more
Nanobodies（Nanobody, Nbs） are a new member of the antibody family, characterized by their relatively small molecular weight, ease of humanization, high affinity, high stability, microbial expression capability, low immunogenicity, strong penetration ability, and good solubility. They have attracted significant attention in basic medical research as well as disease diagnosis and treatment. Introduction to Nanobodies 1. … Read more
The 4th Global Biopharmaceutical Frontier Technology Conference and Exhibition is Open for Registration! The story of the “magic bullet” ADC has clearly not reached its final chapter. With the advent of DS-8201, the global ADC market has become exceptionally vibrant, entering a period of rapid growth. The market’s enthusiasm for ADCs is evident from the … Read more
The Chinese economy is currently at a critical juncture of transformation and structural adjustment. Only by relying on technological innovation can China transition from a phase of rapid growth to a phase of high-quality development. Technological innovation encompasses scientific research and technological advancements, primarily referring to the creation and application of new knowledge, technologies, processes, … Read more